This Article
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerhart, T.
Right arrow Articles by Salzman, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gerhart, T.
Right arrow Articles by Salzman, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?

The Journal of Bone and Joint Surgery, Vol 73, Issue 4 494-502, Copyright © 1991 by Journal of Bone and Joint Surgery, Inc

JOURNAL CONTENTS

Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial

TN Gerhart, HS Yett, LK Robertson, MA Lee, M Smith and EW Salzman
Department of Orthopaedic Surgery, Beth Israel Hospital, Boston, Massachusetts 02115.

In a randomized, prospective trial, a low-molecular-weight heparinoid (Org 10172 [Lomoparan]) was compared with warfarin for efficacy and safety in preventing deep-vein thrombosis in 263 patients who had an operatively treated fracture of the hip. One group of patients received Org 10172 in a dose of 750 units subcutaneously every twelve hours until the ninth postoperative day; on the seventh postoperative day, warfarin was added to the regimen. The other group received only warfarin. Both drugs were begun preoperatively, immediately after the admission evaluation. In the patients who received warfarin, the desired prothrombin time was one and one-half times the control level. Deep-vein thrombosis was detected by 125I-fibrinogen scanning and impedance plethysmography and was confirmed by phlebography and compression ultrasonography. Deep-vein thrombosis was found in nine (7 per cent) of the 132 patients who received Org 10172 and in twenty-eight (21 per cent) of the 131 patients who received warfarin (p less than 0.001). Adverse reactions were not significantly different in the two groups. Major bleeding complications occurred in eight patients in the Org-10172 group, only four of whom were receiving the drug at the time of bleeding, and in five patients who were receiving warfarin (not significant). There was no difference in intraoperative loss of blood or in requirements for transfusion. We concluded that the low-molecular-weight heparinoid Org 10172 is a safe, convenient, effective antithrombotic agent for the prevention of venous thrombosis after an operation for fracture of the hip.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 340S - 380S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. E. Warkentin and A. Greinacher
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 311S - 337S.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
J. F. Schenk, G. Pindur, B. Stephan, S. Mursdorf, F. Mertzlufft, H. Kroll, E. Wenzel, and U. T. Seyfert
On the Prophylactic and Therapeutic Use of Danaparoid Sodium (Orgaran(R)) in Patients With Heparin-Induced Thrombocytopenia
Clinical and Applied Thrombosis/Hemostasis, January 1, 2003; 9(1): 25 - 32.
[Abstract] [PDF]

Home page
 NEJMHome page
B. I. Eriksson, K. A. Bauer, M. R. Lassen, A. G.G. Turpie, and the Steering Committee of the Pentasaccharide in H
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery
N. Engl. J. Med., November 1, 2001; 345(18): 1298 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 TraumaHome page
M. Verstraete
Prevention and treatment of venous thromboembolism after major trauma
Trauma, January 1, 1999; 1(1): 39 - 51.
[Abstract] [PDF]

Home page
 Vasc MedHome page
J.-L. Cracowski, J.-L. Bosson, F. Baloul, C. Moirant, M. Hunt, P. Merloz, P. Carpentier, and A. Franco
Early development of deep-vein thrombosis following hip fracture surgery: the role of venous wall thickening detected by B-mode ultrasonography
Vascular Medicine, November 1, 1998; 3(4): 269 - 274.
[Abstract] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
R. D. Hull and G. F. Pineo
Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism: Current Recommendations
Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 96 - 104.
[Abstract] [PDF]

Home page
 NEJMHome page
J. D. Zuckerman
Hip Fracture
N. Engl. J. Med., June 6, 1996; 334(23): 1519 - 1525.
[Full Text] [PDF]

Home page
 JBJSHome page
M. F. MCDONNELL, S. D. GLASSMAN, J. R. DIMAR II, R. M. PUNO, and J. R. JOHNSON
Perioperative Complications of Anterior Procedures on the Spine*{{dagger}}
J. Bone Joint Surg. Am., June 1, 1996; 78(6): 839 - 47.
[Abstract] [Full Text]

Home page
 CLIN APPL THROMB HEMOSTHome page
R. D. Hull, G. E. Raskob, G. F. Pineo, and R. F. Brant
The Treatment of Proximal Vein Thrombosis with Subcutaneous Low-Mole Molecular-Weight Heparin Compared with Continuous Intravenous Heparin
Clinical and Applied Thrombosis/Hemostasis, March 1, 1995; 1(2): 151 - 159.
[Abstract] [PDF]